Bulletin
Investor Alert

Gamida Cell Ltd.

NAS: GMDA

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Gamida Cell Ltd.

After Hours

 --Quotes are delayed by 20 min

Mar 28, 2023, 7:59 p.m.

GMDA
/zigman2/quotes/207657083/composite

$

0.77

Change

+0.0054 +0.71%

Volume

Volume 68,751

Quotes are delayed by 20 min

/zigman2/quotes/207657083/composite

Today's close

$ 0.68

$ 0.76

Change

+0.08 +12.15%

Day low

Day high

$0.63

$0.77

Open

52 week low

52 week high

$0.56

$4.72

Open

Company Description

Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and un...

Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Boston, MA.

Valuation

Price to Book Ratio

3.47

Enterprise Value to EBITDA

-0.93

Total Debt to Enterprise Value

0.59

Efficiency

Income Per Employee

-534,482.00

Liquidity

Current Ratio

3.88

Quick Ratio

3.88

Cash Ratio

3.77

Profitability

Return on Assets

-59.02

Return on Equity

-125.87

Return on Total Capital

-75.70

Return on Invested Capital

-79.79

Capital Structure

Total Debt to Total Equity

181.44

Total Debt to Total Capital

64.47

Total Debt to Total Assets

53.58

Long-Term Debt to Equity

175.30

Long-Term Debt to Total Capital

62.29

Officers and Executives

Name Age Officer Since Title
Mr. Robert I. Blum 57 2018 Chairman
Ms. Abigail L. Jenkins - 2022 President, Chief Executive Officer & Director
Mr. Michele I. Korfin 50 2020 Chief Operating & Commercial Officer
Mr. Shai Lankry 44 2018 Chief Financial Officer
Dr. Yona Geffen - 2020 Vice President-Research & Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
02/08/2023 Julian Adams
Director 		28,300   Award at $0 per share. 0
02/08/2023 Michele I. Korfin
COO/Chief Commercial Officer 		92,990   Award at $0 per share. 0
02/08/2023 Ronit Simantov
CMO & Chief Scientific Officer 		58,100   Award at $0 per share. 0
02/08/2023 Shai Lankry
Chief Financial Officer 		56,480   Award at $0 per share. 0
02/08/2023 Joshua F. Patterson
General Counsel 		63,000   Award at $0 per share. 0
02/08/2023 Robert I. Blum
Director 		14,200   Award at $0 per share. 0
02/08/2023 Robert I. Blum
Director 		28,300   Award at $0 per share. 0
02/08/2023 Stephen T. Wills
Director 		14,200   Award at $0 per share. 0
02/08/2023 Stephen T. Wills
Director 		28,300   Award at $0 per share. 0
02/08/2023 Shawn Cline Tomasello
Director 		28,300   Award at $0 per share. 0
02/08/2023 Kenneth I. Moch
Director 		28,300   Award at $0 per share. 0
02/08/2023 Anat Cohen-Dayag
Director 		28,300   Award at $0 per share. 0
02/08/2023 Ivan M. Borrello
Director 		28,300   Award at $0 per share. 0
02/08/2023 Naama Halevi-Davidov
Director 		28,300   Award at $0 per share. 0
11/18/2022 Julian Adams
Director 		2,000   Award at $0 per share. 0
11/18/2022 Robert I. Blum
Director 		2,000   Award at $0 per share. 0
11/18/2022 Stephen T. Wills
Director 		2,000   Award at $0 per share. 0
11/18/2022 Shawn Cline Tomasello
Director 		2,000   Award at $0 per share. 0
11/18/2022 Kenneth I. Moch
Director 		2,000   Award at $0 per share. 0
09/30/2022 Abigail L. Jenkins
President and CEO; Director 		16,129   Acquisition at $1.55 per share. 24,999
09/30/2022 Robert I. Blum
Director 		50,000   Acquisition at $1.55 per share. 77,500
09/30/2022 Stephen T. Wills
Director 		9,677   Acquisition at $1.55 per share. 14,999
09/30/2022 Shawn Cline Tomasello
Director 		9,677   Acquisition at $1.55 per share. 14,999
09/19/2022 Abigail L. Jenkins
President and CEO; Director 		250,000   Award at $0 per share. 0
07/27/2022 Julian Adams
Director 		68,800   Award at $0 per share. 0
07/27/2022 Julian Adams
Director 		48,500   Award at $0 per share. 0
06/09/2022 Ivan M. Borrello
Director 		4,000   Award at $0 per share. 0
01/28/2022 Michele I. Korfin
COO/Chief Commercial Officer 		63,800   Award at $0 per share. 0
01/28/2022 Shai Lankry
Chief Financial Officer 		43,000   Award at $0 per share. 0
01/28/2022 Joshua F. Patterson
General Counsel 		51,000   Award at $0 per share. 0
01/28/2022 Anat Cohen-Dayag
Director 		4,000   Award at $0 per share. 0
01/27/2022 Naama Halevi-Davidov
Director 		4,000   Award at $0 per share. 0
/news/latest/company/us/gmda

MarketWatch News on GMDA

  1. Gamida Cell started at buy with $11 stock price target at Alliance Global

    7:08 a.m. Nov. 1, 2021

    - Tomi Kilgore

  3. Gamida Cell started at outperform with $15 stock price target at Oppenheimer

    8:26 a.m. Nov. 21, 2018

    - Tomi Kilgore

/news/nonmarketwatch/company/us/gmda

Other News on GMDA

  3. Gamida Cell (GMDA) Investor Presentation - Slideshow

    3:20 p.m. Nov. 15, 2022

    - Seeking Alpha

  4. 10-Q: GAMIDA CELL LTD.

    5:18 p.m. Nov. 14, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  5. Gamida Cell Ltd. (GMDA)Q3 2022 Earnings Call Transcript

    12:08 p.m. Nov. 14, 2022

    - Seeking Alpha

  6. Gamida Cell GAAP EPS of -$0.29 beats by $0.02

    8:11 a.m. Nov. 14, 2022

    - Seeking Alpha

  7. Notable earnings before Monday's open

    10:23 a.m. Nov. 11, 2022

    - Seeking Alpha

  9. Athersys: Is Big Pharma Sleeping At The Wheel?

    11:43 p.m. Oct. 5, 2022

    - Seeking Alpha

  10. Gamida Cell gains on long-term data for blood cancer therapy

    11:08 a.m. Sept. 29, 2022

    - Seeking Alpha

  13. Gamida Cell shares slide on pricing ~$20M stock offering

    5:01 a.m. Sept. 28, 2022

    - Seeking Alpha

  14. Gamida Cell shares slide after stock offering

    4:18 p.m. Sept. 27, 2022

    - Seeking Alpha

  15. Gamida appoints Emergent’s former head of vaccines as new CEO

    8:17 a.m. Sept. 19, 2022

    - Seeking Alpha

  16. Gamida Cell: Gearing Up For FDA Approval

    10:12 a.m. Aug. 16, 2022

    - Seeking Alpha

  17. Gamida Cell Ltd. (GMDA) Q2 2022 Earnings Call Transcript

    3:00 p.m. Aug. 15, 2022

    - Motley Fool

  19. 10-Q: GAMIDA CELL LTD.

    7:37 a.m. Aug. 15, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  20. Gamida Cell GAAP EPS of -$0.31 misses by $0.02

    7:07 a.m. Aug. 15, 2022

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Gamida Cell Ltd.

116 Huntington Avenue

Boston, Massachusetts 02116

Phone

1 7134006400

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

View SEC Filings

Revenue

N/A

Net Income

$-89.79M

Employees

168.00

Annual Report for GMDA

/news/pressrelease/company/us/gmda

Press Releases on GMDA

  2. Gamida Cell Announces Changes to Board of Directors

    4:30 p.m. March 20, 2023

    - BusinessWire - BZX

  7. Gamida Cell Announces Closing of $25 Million Financing With Highbridge

    8:00 a.m. Dec. 12, 2022

    - BusinessWire - BZX

  9. Gamida Cell Provides Regulatory Update on Omidubicel

    5:52 p.m. Nov. 21, 2022

    - BusinessWire - BZX

  19. Gamida Cell Announces Launch of Public Offering of Ordinary Shares

    4:06 p.m. Sept. 27, 2022

    - BusinessWire - BZX

  21. Loading more headlines...
Link to MarketWatch's Slice.